More articles from 12.01 - Idiopathic interstitial pneumonias

Effects of a palmitate and fructose rich diet on lung fibrosis and inflammation markers in a murine model
K Stiliyanov Atanasov, C Gómez, J Truyols Vives, A Martín-Medina, G Escarrer, E Sala-Llinàs, J Mercader-Barceló

European Respiratory Journal Sep 2022, 60 (suppl 66) 4177; DOI: 10.1183/13993003.congress-2022.4177
The interstitial lung disease (ILD) patient journey in Brazil
A Rubin, L Mota, R Scabello, C Cruz, H Silva

European Respiratory Journal Sep 2022, 60 (suppl 66) 4593; DOI: 10.1183/13993003.congress-2022.4593
Interstitial lung disease with pulmonary hypertension and the potential for inhaled Treprostinil: A single centre perspective
S Ramjug, C Hayton, P Rivera-Ortega, C Leonard, H Morris, K Zakis, J Swale, T Garfoot, K Newman, C Avram, J Blaikley, N Chaudhuri

European Respiratory Journal Sep 2022, 60 (suppl 66) 4242; DOI: 10.1183/13993003.congress-2022.4242
The effect of antifibrotics in patients with different forms of pulmonary fibrosis: data from the Dutch PF registry
A van Batenburg, G Nakshbandi, C Moor, M Wijsenbeek, J Grutters

European Respiratory Journal Sep 2022, 60 (suppl 66) 4442; DOI: 10.1183/13993003.congress-2022.4442
National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
J Salonen, M Purokivi, U Hodgson, R Kaarteenaho

European Respiratory Journal Sep 2022, 60 (suppl 66) 4357; DOI: 10.1183/13993003.congress-2022.4357
Inhaled pirfenidone is associated with better quality of life scores in idiopathic pulmonary fibrosis
G Kim, J Goldin, F Woodhead, C N Thompson, M Shaffer, K Otto, B Montgomery

European Respiratory Journal Sep 2022, 60 (suppl 66) 4625; DOI: 10.1183/13993003.congress-2022.4625
Transcriptomic differences in lung apices and bases in idiopathic pulmonary fibrosis (IPF)
M Wong, C Gamell, M Alhamdoosh, L Mcmillan, N Wilson, Y K Wee, M Staempfli, G Westall, J Jaffar

European Respiratory Journal Sep 2022, 60 (suppl 66) 4364; DOI: 10.1183/13993003.congress-2022.4364
An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
T M Maher, W Forbes, E Bortey, T Sciascia

European Respiratory Journal Sep 2022, 60 (suppl 66) 4404; DOI: 10.1183/13993003.congress-2022.4404
Additive effect of BI 1015550 and nintedanib in patients with IPF
L Richeldi, A Azuma, V Cottin, C Hesslinger, S Stowasser, C Valenzuela, M Wijsenbeek, D Wachtlin, D Zoz, T Maher

European Respiratory Journal Sep 2022, 60 (suppl 66) 4606; DOI: 10.1183/13993003.congress-2022.4606
Data-driven multivariate cohort selection and automated CT scan lung volume measurement identifies disease progression in Idiopathic Pulmonary Fibrosis (IPF)
H Manners, T Mclellan, K Kirov, M Roberts, F Kanavati, G Mckenzie, D Gallagher, J Hainsworth, D Dosanjh, P Molyneaux, A Ruggiero, M Thillai

European Respiratory Journal Sep 2022, 60 (suppl 66) 4502; DOI: 10.1183/13993003.congress-2022.4502

Main menu

User menu

Search

More articles from 12.01 - Idiopathic interstitial pneumonias

Pages

Contact us